As from September 1, 2024, Scandion Oncology A/S, will change Certified Adviser to Vator Securities AB. This information is distributed at the request of the Certified Adviser, Västra Hamnen Corporate Finance AB. For further information, please call Västra Hamnen Corporate Finance AB on +46 40 20 02 50.
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.01. | Scandion Oncology A/S: Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer | Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase I/II... ► Artikel lesen | |
| 30.08.24 | Nasdaq Stockholm AB: Change of Certified Adviser for Scandion Oncology A/S | As from September 1, 2024, Scandion Oncology A/S, will change Certified Adviser
to Vator Securities AB.
This information is distributed at the request of the Certified Adviser, Västra
Hamnen Corporate... ► Artikel lesen | |
| 18.07.24 | Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 2 | At the request of Scandion Oncology, Scandion Oncology equity rights will be
traded on First North Growth Market as from July 19, 2024.
Security name: Scandion Oncology TO 2
--------------------------------------
Short... ► Artikel lesen | |
| 11.07.24 | Nasdaq Stockholm AB: New last trading day for paid subscription units (BTU) of Scandion Oncology | At the request of Scandion Oncology, the last trading day in Scandion
Oncology's paid subscription units will be changed from 2024-07-11 to
2024-07-15.
Instrument: Paid subscription units... ► Artikel lesen |
